679,790 Shares in Teladoc Health, Inc. $TDOC Bought by Empowered Funds LLC

Empowered Funds LLC bought a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 679,790 shares of the health services provider’s stock, valued at approximately $5,765,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after purchasing an additional 5,235 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after buying an additional 10,485 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Teladoc Health by 5.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after buying an additional 24,124 shares during the last quarter. Acadian Asset Management LLC bought a new position in Teladoc Health during the first quarter valued at approximately $615,000. Finally, Envestnet Asset Management Inc. purchased a new position in Teladoc Health during the 2nd quarter valued at approximately $89,000. 76.82% of the stock is currently owned by institutional investors.

Insider Activity

In other Teladoc Health news, insider Fernando M. Rodrigues sold 5,677 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider owned 9,572 shares of the company’s stock, valued at $73,034.36. This trade represents a 37.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. This trade represents a 4.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 39,195 shares of company stock valued at $299,058. 0.70% of the stock is currently owned by company insiders.

Teladoc Health Stock Up 0.2%

Shares of TDOC opened at $6.51 on Monday. The business has a fifty day moving average of $7.94 and a 200 day moving average of $6.65. The company has a market cap of $1.18 billion, a PE ratio of -6.58 and a beta of 2.12. Teladoc Health, Inc. has a 52-week low of $4.40 and a 52-week high of $9.89.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business had revenue of $606.93 million for the quarter, compared to analysts’ expectations of $615.44 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. The business’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, research analysts anticipate that Teladoc Health, Inc. will post -0.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TDOC has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Canaccord Genuity Group dropped their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Citigroup reduced their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Finally, Bank of America upped their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.54.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.